New Research Report Highlights Exosome Tech Leadership and Upgraded Valuation

INOVIQ (ASX:IIQ): New Research Report Highlights Exosome Tech Leadership and Upgraded Valuation

Excited to share the latest MST Access research (Analyst Reports | INOVIQ) from analyst Chris Kallos on INOVIQ, a leader in exosome-powered diagnostics and therapeutics. The new report underscores INOVIQ’s position at the forefront of the rapidly growing exosome market, with breakthrough advances in cancer care.

Key Highlights:

• Exosome Tech Leadership: Proven platform with on-market research tools and a high-value pipeline across diagnostics and therapeutics.
• Ovarian Cancer Screening Test: New ASCO 2025 data shows IIQ’s test achieved 77% all-stage and 100% stage I/II sensitivity at >99.6% specificity—potentially best-in-class for screening ovarian cancer in asymptomatic women.
• Triple Negative Breast Cancer Therapy: Proprietary CAR-exosome program demonstrates 88% tumour cell death in vitro—potentially first-in-class CAR-exosome therapy with cost, safety, and efficacy advantages over autologous CAR-T therapies.

Valuation Update:
Valuation increased to A$4.37/share (from A$3.42) on the back of strong progress in EXO-OC™ ovarian cancer test and the addition of the CAR-EV program for TNBC.

INOVIQ is advancing next-gen solutions to transform cancer care and improve patient outcomes. For more details, check out the full report or visit INOVIQ’s website.

I had sent this to the email bin before I saw its not on here